Interleukin-6 upregulates GP96 expression in breast cancer

Journal of Surgical Research

Volumn 69, Issue 1, 1997, Pages 145-149

  Haverty, Amanda Anne ^a   Harmey, Judith H ^a   Redmond, H Paul ^a   Bouchier Hayes, David J ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; GLUCOSE REGULATED PROTEIN; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 6;

ANIMAL CELL; BREAST CARCINOMA; BREAST METASTASIS; CANCER RESISTANCE; CELL INTERACTION; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN INDUCTION; STRESS;

EID: 0031127798     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1997.5036     Document Type: Conference Paper

References (47)

1. 1. Venetianer, A., Pirity, M., and Hever-Szabo, A. The function of heat-shock proteins in stress tolerance. Cell Biol. Int. 18: 605-615, 1994.
2. 2. Welch, W. J. The mammalian heat shock (or stress) response: A cellular defense mechanism. Adv. Exp. Med. Biol. 225: 287-304, 1987.
3. 3. Lee, A. S. Mammalian stress response: Induction of glucose-regulated protein family. Curr. Opin. Cell Biol. 4: 267-273, 1992.
4. 4. Kang, H. S., and Welch, W. J. Characterization and purification of the 94 kDa glucose regulated protein. J. Biol. Chem. 266: 5643-5649, 1991.
5. 2+-calmodulin-regulated actin-binding protein. J. Biol. Chem. 264: 15083-15087, 1989.
6. 2+ ATPase regulation. J. Biol. Chem. 271: 44, 27788-27794, 1996.
7. 7. Trump, B. F., and Berezesky, I. K. Calcium-mediated cell injury and cell death. FASEB J. 9, 219-228, 1995.
8. 8. Menoret, A., Meflah, K., and Lependu, J. Expression of the 100-kDa glucose regulated protein (GRP100/endoplasmin) is associated with tumorigenicity in a model of rat colon adenocarcinoma. Int. J. Cancer 56: 400-405, 1994.
9. 9. Ciocca, D. R., Fuqua, S. A., Lock-Lim, S., et al. Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res. 52: 3648-3654, 1992.
10. 10. Li, G. C. Heat shock proteins: Role in thermotolerance, drug resistance, and relationship to DNA topoisomerases. NCI Monogr. 4: 99-103, 1987.
11. 11. Li, Z., and Srivastava, P. K. Tumor rejection antigen gp96/grp94 is an ATPase: Implications for protein folding and antigen presentation. EMBO J. 11: 3143-3151, 1993.
12. 12. Srivastava, P. K., DeLeo, A. B., and Old, L. J. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc. Natl. Acad. Sci. USA 83: 3407-3411, 1986.
13. 13. Srivastava, P. K., Udono, H., Blachere, N. E., and Li, Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39: 93-98, 1994.
14. 14. Kishimoto, T. The biology of Interleukin-6. Blood 74: 1-10, 1989.
15. 15. Lee, J. D., Sievers, T. M., Shotzko, M., et al. Interleukin-6 production by human melanoma cell lines. Cytokine Res. 11: 161-166, 1992.
16. 16. Hutchins, D., and Steel, C. M. Regulation of ICAM-1 Expression in human breast cancer cell lines by Interleukin-6 and fibroblast growth factors. Int. J. Cancer 58: 80-84, 1994.
17. 17. Blais, Y., Sugimoto, K., Carrière, M. C., Haagensen, D. E., Labrie, F., and Simard, J. Interleukin-6 inhibits the potent stimulatory action of androgens, glucocorticoids and interleukin-1 alpha on apolipoprotein D and GCDFP-15 expression in human breast cancer cells. Int. J. Cancer 62: 6, 732-737, 1995.
18. 18. Basolo, F., Fiore, L., Fontanini, G., et al. Expression of and response to Interleukin-6 (IL6) in human mammary tumours. Cancer Res. 56: 3118-3122, 1996.
19. 19. Chen, L., Shulman, L. M., and Revel, M. IL-6 receptors and sensitivity to growth inhibition by IL-6 in clones of human breast carcinoma cells. J. Biol. Regul. Homeost. Agents 5: 125-136, 1991.
20. 20. Shenkin, A., Fraser, W. D., Series, J., et al. The serum Interleukin-6 response to elective surgery. Lymphokine Res. 8: 123-127, 1989.
21. 21. Tang, G-J., Kuo, C-D., Yen, T-C., et al. Perioperative plasma concentrations of tumor necrosis factor-α and interleukin-6 in infected patients. Crit. Care Med. 24: 423-428, 1996.
22. 22. West, M. A., Li, M. H., Seatter, S. C., and Bubrick, M. P. Preexposure to hypoxia or septic stimuli differently regulates endotoxin release of tumour necrosis factor, interleukin-6, interleukin-1, prostaglandin E2, nitric oxide and superoxide by macrophages. J. Trauma 37(1): 82-90, 1994.
23. 23. Abe, M., Ouchi, N., Harada, Y., Mori, S., Rishiki, H., and Kumagai, K. Elevated serum levels of interleukin-6 in breast cancer patients with viseceral metastases. Nippon Geka Gakkai Zasshi 93: 1, 107, 1992.
24. 24. Kyrstsonis, M. C., Dedoussis, G., Baxevanis, C., et al. Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM). Br. J. Haematol. 92: 420-422, 1996.
25. 25. Oka, M., Yamamoto, K., Takahashi, M., et al. Relationship between serum interleukin 6, various disease parameters, and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res. 56: 2776-2780, 1996.
26. 26. Yan, S. F., Tritto, I., Pinsky, D., et al. Induction of Interleukin-6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor Interleukin-6. J. Biol. Chem. 270: 11463-11471, 1995.
27. 27. Ala, Y., Palluy, O., Favero, J., Bonne, C., Modat, G., and Dornand, J. Hypoxia/reoxygenation stimulates endothelial cells to promote interleukin-1 and interleukin-6 production. Effects of free radical scavengers. Agents Actions 37(1-2): 134-139, 1992.
28. 28. Tamm, I., Cardinale, I., and Murphy, J. S. Decreased adherance of interleukin-6 treated breast carcinoma cells can lead to separation from neighbours after mitosis. Proc. Natl. Acad. Sci. USA 88: 4414-4418, 1991.
29. 29. Tamm, I., Kikuchi, T., Cardinale, I., and Krueger, J. G. Cell-adhesion-disrupting action of Interleukin-6 in human ductal carcinoma cells. Proc. Natl. Acad. of Sci. USA 91: 3329-3333, 1994.
30. 30. Nakai, A., Kawatani, T., Ohi, S., et al. Expression and phosphorylation of BiP/GRP78, a molecular chaperone in the endoplasmic reticulum, during the differentiation of a mouse myeloblastic cell line. Cell Struc. Funct. 20: 33-39, 1995.
31. 31. Adams, E. F., Rafferty, B., and White, M. C. Interleukin-6 is secreted by breast fibroblasts and stimulates 17-β-oestradiol oxidoreductase activity of MCF-7 cells: Possible paracrine regulation of breast 17-β-oestradiol levels. Int. J. Cancer 49: 118-121, 1991.
32. 32. Pulkki, K., Pelliniemi, T. T., Rajamaki, A., et al. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Br. J. Haematol. 92: 370-374, 1996.
33. 33. Schwabe, M., Cox, G. W., Bosco, M. C., Prohaska, R., and Kung, H. F. Multiple cytokines inhibit interleukin-6 dependent murine hybridoma/plasmacytoma proliferation. Cell. Immunol. 168: 117-121, 1996.
34. 34. Reichner, J. S., Mulligan, J. A., Palla, M. E., et al. Interleukin-6 production by rat hepatocellular carcinoma cells is associated with metastatic potential but not with tumorigenicity. Arch. Surg. 131: 360-365, 1996.
35. 35. Sunderkötter, C., Steinbrink, K., Goebler, M., et al. Macrophages and angiogenesis. J. Leukocyte Biol. 55: 410-415, 1995.
36. 36. Mantovani, G., Maccio, A., Versace, R., Pisano, M., Lai, P., Esu, S., Ghiani, M., Dessi, D., Turnu, E., and Santona, M. C. Tumor associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC. J. Mol. Med. 73: 409-416, 1995.
37. 37. Levy, A. P., Levy, N. S., and Goldberg, M. A. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem. 271: 2746-2753, 1996.
38. 38. Cohen, T., Nahari, D., Cerem, L. W., et al. IL-6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. 271: 736-774, 1996.
39. 2+ ATPases. J. Cell Biol. 124: 351-363, 1994.
40. 40. Xue, S. B., Zhang, H. Q., Cheng, R. X., and Li, S. W. Increase of calcium levels at interphase in NIH 3T3 cells. Sci. China. B 36: 314-318, 1993.
41. 0 and progression into S phase. Mol. Cell. Biol. 4: 293-302, 1993.
42. 42. Csermely, P., Miyata, Y., Schnaider, T., and Yahara, I. Autophosphorylation of grp94 (endoplasmin). J. Biol. Chem. 270: 6381-6388, 1995.
43. 43. Gala, S. E., and Jones, L. R. GRP94 resides within cardiac sarcoplasmic reticulum vesicles and is phosphorylated by Casein Kinase II. J. Biol. Chem. 269: 5926-5931, 1994.
44. 44. Miyata, Y., and Yahara, I. Interaction between casein kinase II and the 90 kDa stress protein, HSP90. Biochemistry 34: 8123-8129, 1995.
45. 45. Agostinis, P., Goris, J., Pinna, L. A., and Merlevede, W. Regulation of casein kinase 2 by phosphorylation/dephosphorylation. Biochem. J. 248: 785-789, 1987.
46. 46. Cummings, J., and Smyth, J. F. DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann. Oncol. 4: 533-543, 1993.
47. 47. Li, G. C. Heat shock proteins: role in thermotolerance, drug resistance, and relationship to DNA topoisomerases. NCI Monogr. 4: 99-103, 1987.